ZW 251
Alternative Names: ZW-251Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator Zymeworks
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 25 Oct 2024 Zymeworks announces intention to submit an IND application and other non-US applications for Liver cancer in the second half of 2025
- 23 Oct 2024 Pharmacokinetics, pharmacodynamics and safety data from preclinical trials in indication) presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)
- 04 Jan 2024 Zymeworks plans a first in human clinical trial for Liver cancer in 2025